Language
中文
繁體
EN
About
Overview
Team
History
Branch
Honor
Culture
Science&Products
R & D Platform
Product pipeline
Product Introduction
Patient
Previous research
Patient Recruitment
Blog
Company News
Industry news
Investor
Prospectus
Financial report
Announcement and Circular
Corporate Governance
Investor Inquiry
Cooperation
Careers
Talent Strategy
Social Recruitment
Campus Recruitment
Contact
Message
English
español
Русский
Patient Area
Immunotech Biopharm (06978.HK) was invited to participate in the "2022 Zhitong Finance Capital Market Annual Conference".
2022-01-13
Immunotech Biopharm (06978.HK): The founder and controlling shareholder has added a lock-up commitment, and the commercialization progress of EAL® is going smoothly with optimistic expectations.
2022-01-14
Immunotech Biopharm (06978.HK) has officially submitted a Pre-IND application for the RC19D2 cell injection (Dino-run injection).
2022-02-10
Immunotech Biopharm (06978.HK) has completed the enrollment of the first subject in the Phase I clinical trial of 6B11-OCIK injection.
The discussion meeting for the clinical protocol of EAL®-GC (gastric cancer) by Immunotech Biopharm (06978.HK) was successfully held.
Immunotech Biopharm (06978.HK) has been included in the 2021 "China Science and Technology Innovation" leading technology list.
2022-02-11
Public announcement before the approval of the environmental impact assessment for the industrialization project of new tumor products - immune cell products by Beijing Immunotech Biopharm Products Co., Ltd.
Media Attention | Market Indicators Reveal Investment Value, Immunotech Biopharm (06978) Included in the Hang Seng Composite Index
2022-02-21
Media Attention | Immunotech Biopharm (6978.HK): Successfully Included in the Hang Seng Composite Index, Highlighting Investment Value with Multiple Benefits
2022-03-02
Immunotech Biopharm (6978.HK) has been included in the Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect, effective today.
2022-03-07
